ID

13875

Descrição

Pre-Prostatectomy Lovastatin on Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01478828

Link

https://clinicaltrials.gov/show/NCT01478828

Palavras-chave

Versões (1)
  1. 13/03/2016 13/03/2016 -
Transferido a

13 de março de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Prostate Cancer NCT01478828

Inglês

Eligibility Prostate Cancer NCT01478828

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. adenocarcinoma of the prostate, without evidence of spread beyond to lymph nodes, bone, or visceral organs, stage t1c or higher.
Descrição

Adenocarcinoma of prostate; Tumor stage; lymph nodes; bone

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0007112
UMLS CUI [2]
C1300072
UMLS CUI [3]
C0024204
UMLS CUI [4]
C0262950
2. tumor gleason sum of 7 (4+3 and 3+4 allowed) in at least one core, after central review of prostate biopsy at johns hopkins. however, in accordance with standard clinical practices, adenocarcinoma must be present in at least two discrete biopsy sections ( may vary in gleason score).
Descrição

gleason score; prostate biopsy; adenocarcinoma

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3203027
UMLS CUI [2]
C0194804
UMLS CUI [3]
C0001418
3. age ≥18 years of age.
Descrição

age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
4. radical prostatectomy scheduled at johns hopkins.
Descrição

radical prostatectomy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0194810
5. willingness to sign and ability to understand informed consent.
Descrição

informed consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
6. no history of treatment with any statin-class medication within 6 months of entry into the trial.
Descrição

medication statin

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0360714
7. ecog (eastern cooperative oncology group) performance status 0-1.
Descrição

ecog performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
8. adequate bone marrow, hepatic, and renal function as determined by:
Descrição

bone marrow function; hepatic function; renal function

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0412480
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
wbc (white blood cells) >3,500 cells/mm3 anc (absolute neutrophil count) >1,500 cells/mm3 hemoglobin >9 g/dl platelet count >100,000 cells/mm3 serum creatinine < 2.6 mg/dl serum bilirubin <2 mg/dl alt (alanine aminotransferase), ast (aspartate aminotransferase), and alkaline phosphatase <2 times the upper limit of normal triglycerides and total cholesterol <3 times the upper limit of normal
Descrição

white blood cells; absolute neutrophil count; platelets; hemoglobin; serum bilirubin; Alanine aminotransferase; aspartate aminotransferase; serum creatinine; alkaline phosphatase; total cholesterol; triglycerides

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023508
UMLS CUI [2]
C0948762
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0518015
UMLS CUI [5]
C0428441
UMLS CUI [6]
C0201836
UMLS CUI [7]
C0201899
UMLS CUI [8]
C0201976
UMLS CUI [9]
C0002059
UMLS CUI [10]
C0543421
UMLS CUI [11]
C0202236
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients with evidence of metastatic prostate cancer, including bone, visceral, brain, and lymph node metastases.
Descrição

metastatic prostate cancer

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0936223
2. other histologic prostate cancers, including ductal, sarcomatous, lymphoma, small cell, and neuroendocrine tumors.
Descrição

prostate cancer

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0019638
UMLS CUI [1,2]
C0600139
3. uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy including active liver disease, unexplained persistent elevation of serum transaminases, or medications that interfere with the metabolism of lovastatin, or gastrointestinal disease that would limit the ability to swallow or take oral medications or absorb them.
Descrição

Compliance behavior Limited Comorbidity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
4. concurrent malignancy other than prostate cancer.
Descrição

malignancy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0006826
5. inability to provide informed consent.
Descrição

informed consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
6. concomitant use of azole antifungals, cyclosporine, clarithromycin, erythromycin, fibric acid derivatives, lopinavir/ritonavir, niacin, ritonavir/saquinavir
Descrição

concomitant medication antifungals cyclosporine

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C0003308
UMLS CUI [1,3]
C0010592
7. prior chemotherapy, radiation therapy, biologic therapy, or immunotherapy for prostate cancer.
Descrição

Study Subject Participation Status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2348568
8. poor performance status (ecog >1).
Descrição

ecog performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
9. prostatectomy at other hospital other than johns hopkins.
Descrição

prostatectomy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0033573
10. prior history of allergy or severe reaction to statins or statin derivatives.
Descrição

hypersensitivity statin

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0360714
Voltar ao início da página

Similar models

Eligibility Prostate Cancer NCT01478828

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate; Tumor stage; lymph nodes; bone
Item
1. adenocarcinoma of the prostate, without evidence of spread beyond to lymph nodes, bone, or visceral organs, stage t1c or higher.
boolean
C0007112 (UMLS CUI [1])
C1300072 (UMLS CUI [2])
C0024204 (UMLS CUI [3])
C0262950 (UMLS CUI [4])
gleason score; prostate biopsy; adenocarcinoma
Item
2. tumor gleason sum of 7 (4+3 and 3+4 allowed) in at least one core, after central review of prostate biopsy at johns hopkins. however, in accordance with standard clinical practices, adenocarcinoma must be present in at least two discrete biopsy sections ( may vary in gleason score).
boolean
C3203027 (UMLS CUI [1])
C0194804 (UMLS CUI [2])
C0001418 (UMLS CUI [3])
age
Item
3. age ≥18 years of age.
boolean
C0001779 (UMLS CUI [1])
radical prostatectomy
Item
4. radical prostatectomy scheduled at johns hopkins.
boolean
C0194810 (UMLS CUI [1])
informed consent
Item
5. willingness to sign and ability to understand informed consent.
boolean
C0021430 (UMLS CUI [1])
medication statin
Item
6. no history of treatment with any statin-class medication within 6 months of entry into the trial.
boolean
C0013227 (UMLS CUI [1,1])
C0360714 (UMLS CUI [1,2])
ecog performance status
Item
7. ecog (eastern cooperative oncology group) performance status 0-1.
boolean
C1520224 (UMLS CUI [1])
bone marrow function; hepatic function; renal function
Item
8. adequate bone marrow, hepatic, and renal function as determined by:
boolean
C0412480 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
white blood cells; absolute neutrophil count; platelets; hemoglobin; serum bilirubin; Alanine aminotransferase; aspartate aminotransferase; serum creatinine; alkaline phosphatase; total cholesterol; triglycerides
Item
wbc (white blood cells) >3,500 cells/mm3 anc (absolute neutrophil count) >1,500 cells/mm3 hemoglobin >9 g/dl platelet count >100,000 cells/mm3 serum creatinine < 2.6 mg/dl serum bilirubin <2 mg/dl alt (alanine aminotransferase), ast (aspartate aminotransferase), and alkaline phosphatase <2 times the upper limit of normal triglycerides and total cholesterol <3 times the upper limit of normal
boolean
C0023508 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0518015 (UMLS CUI [4])
C0428441 (UMLS CUI [5])
C0201836 (UMLS CUI [6])
C0201899 (UMLS CUI [7])
C0201976 (UMLS CUI [8])
C0002059 (UMLS CUI [9])
C0543421 (UMLS CUI [10])
C0202236 (UMLS CUI [11])
Item Group
C0680251 (UMLS CUI)
metastatic prostate cancer
Item
1. patients with evidence of metastatic prostate cancer, including bone, visceral, brain, and lymph node metastases.
boolean
C0936223 (UMLS CUI [1])
prostate cancer
Item
2. other histologic prostate cancers, including ductal, sarcomatous, lymphoma, small cell, and neuroendocrine tumors.
boolean
C0019638 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
Compliance behavior Limited Comorbidity
Item
3. uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy including active liver disease, unexplained persistent elevation of serum transaminases, or medications that interfere with the metabolism of lovastatin, or gastrointestinal disease that would limit the ability to swallow or take oral medications or absorb them.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
malignancy
Item
4. concurrent malignancy other than prostate cancer.
boolean
C0006826 (UMLS CUI [1])
informed consent
Item
5. inability to provide informed consent.
boolean
C0021430 (UMLS CUI [1])
concomitant medication antifungals cyclosporine
Item
6. concomitant use of azole antifungals, cyclosporine, clarithromycin, erythromycin, fibric acid derivatives, lopinavir/ritonavir, niacin, ritonavir/saquinavir
boolean
C2347852 (UMLS CUI [1,1])
C0003308 (UMLS CUI [1,2])
C0010592 (UMLS CUI [1,3])
Study Subject Participation Status
Item
7. prior chemotherapy, radiation therapy, biologic therapy, or immunotherapy for prostate cancer.
boolean
C2348568 (UMLS CUI [1])
ecog performance status
Item
8. poor performance status (ecog >1).
boolean
C1520224 (UMLS CUI [1])
prostatectomy
Item
9. prostatectomy at other hospital other than johns hopkins.
boolean
C0033573 (UMLS CUI [1])
hypersensitivity statin
Item
10. prior history of allergy or severe reaction to statins or statin derivatives.
boolean
C0020517 (UMLS CUI [1,1])
C0360714 (UMLS CUI [1,2])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial